They found that the delivery and treatment efficiency with nanoparticles was improved with UTMD and successfully inhibited the proliferation of tumor cells, achieving a targeted combination of sonodynamic therapy and antibody therapy with nanoparticles for treating HER2-positive gastric cancer (Figure 4). The gene discussed is ERBB2; the disease is neoplasm.